ANGPTL3 and atherosclerosis: In an early multi-cohort exome-sequencing study centered on DiscovEHR, among 13,102 patients with coronary artery disease (CAD) and 40,430 controls, carriers of ANGPTL3 LoF variants had an odds ratio (OR) for CAD of 0.59, replicated across four independent populations; the same paper used pharmacologic antagonism in humans and atherosclerotic mice for causal validation, forming an evidence chain from genetics to pharmacology to atherosclerosis phenotypes (9).